Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta‐analysis

Abstract

BackgroundLow muscle mass occurs in patients with rheumatoid arthritis without weight loss; this condition is referred as rheumatoid cachexia. The aim of the current study was to perform a systematic review with meta‐analysis to determine the rheumatoid cachexia prevalence.MethodsA systematic review with meta‐analysis of observational studies published in English, between 1994 and 2016, was conducted using MEDLINE (via PubMed) and other relevant sources. Search strategies were based on pre‐defined keywords and medical subject headings. The methodological quality of included studies was assessed using the Newcastle‐Ottawa Scale. Meta‐analysis was used to estimate the prevalence, and because studies reported different methods and criteria to estimate body composition and prevalence of rheumatoid cachexia, subgroup analyses were performed. Meta‐regression adjusted for the 28‐joint disease activity score and disease duration (years) was performed (significance level at P ≤ 0.05).ResultsOf 136 full articles (one duplicate publication) screened for inclusion in the study, eight were included. The estimated overall prevalence of rheumatoid cachexia was 19% [95% confidence interval (CI) 07–33%]. This prevalence was 29% (95% CI 15–46%) when body composition was measured by dual‐energy X‐ray absorptiometry. When the diagnostic criteria were fat‐free mass index below the 10th percentile and fat mass index above the 25th percentile, rheumatoid cachexia prevalence was 32% (95% CI 14–52%). The 28‐joint disease activity score and disease duration had no influence on the estimated prevalence of rheumatoid cachexia (P > 0.05). Most studies were rated as having moderate methodological quality.ConclusionsMeta‐analysis showed a prevalence of rheumatoid cachexia of 15‐32%, according to different criteria, demonstrating that this condition is a frequent comorbidity of rheumatoid arthritis. To better understand its clinical impact, more studies using standardized definitions and prospective evaluations are urgently needed.

Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis

“…studies where participants lost weight while participants in other studies gained weight. Indeed, some of the primary diseases for which patients were treated with TNF-a blockers, specifically Crohn's disease and rheumatoid arthritis, are often associated with weight loss (Alastair et al, 2011;Santo et al, 2018). Therefore, weight gain during anti-TNF-a therapy may be interpreted as a restoration of normal body weight.…”

Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia

“…Coming from the Greek words ‘kakos’ and ‘hexis’, cachexia means ‘bad condition’ and has been clinically described as long as 2000 years ago by Hippocrates . Cachexia is a multifactorial syndrome associated with numerous chronic or end stage diseases, such as cancer, acquired immunodeficiency syndrome (AIDS), congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis and tuberculosis among others …”

Figures of the Heart Failure Association: Andrew J. Stewart Coats, President‐Elect, 2018–2020

“…The field has exploded since and remains of considerable interest . I have published many papers since then, a reflection of the fantastic people I have worked with over the years, but my most recent change in direction is studying cancer cachexia, following work that Stefan Anker and I did together way back in the late 90's, showing the similarity of cardiac cachexia to other chronic illness‐related cachexias, as summarized in many papers, in a new journal published by a new society in a field that did not even exist when Stefan Anker joined me, and that is now a major field in its own right…”